| Literature DB >> 23881275 |
Feng Qian1, Lisa Chung, Wei Zheng, Vincent Bruno, Roger P Alexander, Zhong Wang, Xiaomei Wang, Sebastian Kurscheid, Hongyu Zhao, Erol Fikrig, Mark Gerstein, Michael Snyder, Ruth R Montgomery.
Abstract
The West Nile virus (WNV) is an emerging infection of biodefense concern and there are no available treatments or vaccines. Here we used a high-throughput method based on a novel gene expression analysis, RNA-Seq, to give a global picture of differential gene expression by primary human macrophages of 10 healthy donors infected in vitro with WNV. From a total of 28 million reads per sample, we identified 1,514 transcripts that were differentially expressed after infection. Both predicted and novel gene changes were detected, as were gene isoforms, and while many of the genes were expressed by all donors, some were unique. Knock-down of genes not previously known to be associated with WNV resistance identified their critical role in control of viral infection. Our study distinguishes both common gene pathways as well as novel cellular responses. Such analyses will be valuable for translational studies of susceptible and resistant individuals--and for targeting therapeutics--in multiple biological settings.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23881275 PMCID: PMC3738954 DOI: 10.3390/v5071664
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.048
Figure 1Differential gene expression of human macrophages infected with West Nile virus (WNV). (a) MA plots of RNA-seq data. The M (log fold change) of each transcript between mock and infected pair is plotted against A (average log concentration/expression level) of each mock and infected pair. In these plots, each point represents an annotated transcript. The black dots reflect no change and the red dots represent transcripts with 4-fold change by edgeR analysis. The straight lines in each plot reflect zero expression in one condition and nonzero expression in the other condition. (b) Heatmap for 1,514 differentially expressed transcripts (Bayesian DE paired analysis) in human macrophages infected with WNV using hierarchical clustering analysis. Red, black and green colors indicate gene expression above, equal to and below the mean, respectively, for subjects #1–10.
Results of functional annotation clustering.
| Category | Term | Count | PValue | FDR |
|---|---|---|---|---|
|
|
| |||
| GO: BP | GO:0006952~defense response | 101 | 2.50 × 10−25 | 4.53 × 10−22 |
| GO: BP | GO:0006954~inflammatory response | 64 | 3.66 × 10−20 | 6.64 × 10−17 |
| GO: BP | GO:0009611~response to wounding | 83 | 1.80 × 10−19 | 3.27 × 10−16 |
|
|
| |||
| GO: BP | GO:0001775~cell activation | 46 | 2.83 × 10−11 | 5.13 × 10−8 |
| GO: BP | GO:0045321~leukocyte activation | 40 | 2.67 × 10−10 | 4.84 × 10−7 |
| GO: BP | GO:0046649~lymphocyte activation | 34 | 3.07 × 10−9 | 5.57 × 10−6 |
| GO: BP | GO:0042110~T cell activation | 26 | 6.22 × 10−9 | 1.13 × 10−5 |
|
|
| |||
| SP_PIR_KEYWORDS | inflammatory response | 26 | 4.45 × 10−15 | 6.43 × 10−12 |
| SP_PIR_KEYWORDS | chemotaxis | 22 | 7.21 × 10−12 | 1.04 × 10−8 |
| GO: MF | GO:0005125~cytokine activity | 37 | 2.14 × 10−11 | 3.31 × 10−8 |
| SP_PIR_KEYWORDS | cytokine | 33 | 7.05 × 10−11 | 1.02 × 10−7 |
| GO: MF | GO:0042379~chemokine receptor binding | 18 | 1.62 × 10−10 | 2.50 × 10−7 |
| INTERPRO | IPR001811:Small chemokine, interleukin-8-like | 16 | 3.86 × 10−10 | 6.24 × 10−7 |
| GO: MF | GO:0008009~chemokine activity | 17 | 5.38 × 10−10 | 8.32 × 10−7 |
| SMART | SM00199:SCY | 16 | 2.96 × 10−9 | 3.89 × 10−6 |
| KEGG_PATHWAY | hsa04060:Cytokine-cytokine receptor interaction | 44 | 4.30 × 10−9 | 5.16 × 10−6 |
| SP_PIR_KEYWORDS | inflammation | 12 | 5.28 × 10−9 | 7.64 × 10−6 |
| GO: BP | GO:0006935~chemotaxis | 27 | 2.20 × 10−7 | 3.99 × 10−4 |
| GO: BP | GO:0042330~taxis | 27 | 2.20 × 10−7 | 3.99 × 10−4 |
| GO: CC | GO:0005615~extracellular space | 65 | 2.68 × 10−7 | 3.73 × 10−4 |
| KEGG_PATHWAY | hsa04062:Chemokine signaling pathway | 32 | 5.92 × 10−7 | 7.10 × 10−4 |
| GO: BP | GO:0007626~locomotory behavior | 35 | 2.35 × 10−6 | 4.26 × 10−3 |
| PIR_SUPERFAMILY | PIRSF001950:small inducible chemokine, C/CC types | 9 | 1.28 × 10−5 | 1.78 × 10−2 |
| INTERPRO | IPR000827:Small chemokine, C-C group, conserved site | 9 | 1.66 × 10−5 | 2.68 × 10−2 |
|
|
| |||
| GO: BP | GO:0001817~regulation of cytokine production | 33 | 1.03 × 10−9 | 1.86 × 10−6 |
| GO: BP | GO:0051240~positive regulation of multicellular organismal process | 32 | 3.97 × 10−6 | 7.21 × 10−3 |
| GO: BP | GO:0001819~positive regulation of cytokine production | 17 | 1.47 × 10−5 | 2.67 × 10−2 |
|
|
| |||
| GO: BP | GO:0002237~response to molecule of bacterial origin | 20 | 6.81 × 10−8 | 1.24 × 10−4 |
| GO: BP | GO:0034097~response to cytokine stimulus | 19 | 9.11 × 10−8 | 1.65 × 10−4 |
| GO: BP | GO:0032496~response to lipopolysaccharide | 18 | 3.37 × 10−7 | 6.11 × 10−4 |
| GO: BP | GO:0009617~response to bacterium | 26 | 2.43 × 10−5 | 4.41 × 10−2 |
|
|
| |||
| GO: BP | GO:0042981~regulation of apoptosis | 87 | 1.03 × 10−10 | 1.86 × 10−7 |
| GO: BP | GO:0043067~regulation of programmed cell death | 87 | 1.65 × 10−10 | 3.00 × 10−7 |
| GO: BP | GO:0010941~regulation of cell death | 87 | 1.99 × 10−10 | 3.61 × 10−7 |
| GO: BP | GO:0043065~positive regulation of apoptosis | 48 | 1.20 × 10−6 | 2.18 × 10−3 |
| GO: BP | GO:0043068~positive regulation of programmed cell death | 48 | 1.46 × 10−6 | 2.65 × 10−3 |
| GO: BP | GO:0010942~positive regulation of cell death | 48 | 1.67 × 10−6 | 3.03 × 10−3 |
| GO: BP | GO:0006916~anti-apoptosis | 27 | 2.66 × 10−5 | 4.82 × 10−2 |
| GO: BP | GO:0006917~induction of apoptosis | 36 | 2.75 × 10−5 | 4.98 × 10−2 |
|
|
| |||
| GO: BP | GO:0002684~positive regulation of immune system process | 42 | 1.05 × 10−11 | 1.91 × 10−8 |
| GO: BP | GO:0050865~regulation of cell activation | 29 | 1.06 × 10−7 | 1.92 × 10−4 |
| GO: BP | GO:0002694~regulation of leukocyte activation | 28 | 1.26 × 10−7 | 2.29 × 10−4 |
| GO: BP | GO:0051249~regulation of lymphocyte activation | 26 | 1.75 × 10−7 | 3.17 × 10−4 |
| GO: BP | GO:0050671~positive regulation of lymphocyte proliferation | 15 | 5.79 × 10−7 | 1.05 × 10−3 |
| GO: BP | GO:0032946~positive regulation of mononuclear cell proliferation | 15 | 7.35 × 10−7 | 1.33 × 10−3 |
| GO: BP | GO:0070665~positive regulation of leukocyte proliferation | 15 | 7.35 × 10−7 | 1.33 × 10−3 |
| GO: BP | GO:0050867~positive regulation of cell activation | 21 | 1.04 × 10−6 | 1.88 × 10−3 |
| GO: BP | GO:0050670~regulation of lymphocyte proliferation | 18 | 1.04 × 10−6 | 1.89 × 10−3 |
| GO: BP | GO:0032944~regulation of mononuclear cell proliferation | 18 | 1.24 × 10−6 | 2.26 × 10−3 |
| GO: BP | GO:0070663~regulation of leukocyte proliferation | 18 | 1.24 × 10−6 | 2.26 × 10−3 |
| GO: BP | GO:0002696~positive regulation of leukocyte activation | 20 | 2.08 × 10−6 | 3.78 × 10−3 |
| GO: BP | GO:0051251~positive regulation of lymphocyte activation | 19 | 2.30 × 10−6 | 4.17 × 10−3 |
| GO: BP | GO:0050863~regulation of T cell activation | 20 | 9.40 × 10−6 | 1.71 × 10−2 |
|
|
| |||
| GO: BP | GO:0043122~regulation of I-kappaB kinase/NF-kappaB cascade | 21 | 5.63 × 10−7 | 1.02 × 10−3 |
| GO: BP | GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB cascade | 19 | 2.30 × 10−6 | 4.17 × 10−3 |
| GO: BP | GO:0010647~positive regulation of cell communication | 39 | 3.50 × 10−6 | 6.36 × 10−3 |
| GO: BP | GO:0010740~positive regulation of protein kinase cascade | 25 | 5.99 × 10−6 | 1.09 × 10−2 |
Figure 2Correlation of WNV infection with change in expression of genes identified by genome-wide RNAi screen. Plot represents average expression (FPKM) of ~180 host susceptibility factors (HSF) genes in mock (●) and ~13 host resistance factors (HRF) genes (◆) samples with uninfected samples shown in open symbols. For all 10 samples, the average expression (FPKM) of HSF genes increases while the average expression of HRF genes decreases from mock to infected samples.
Figure 3Effect of RNAi knockdown on WNV infection. Primary macrophages from healthy volunteers were transfected using the Nucleofection technology with siRNA targeting the genes shown and a non-targeting (nt) control siRNA. (a) The efficiency of RNAi knockdown after 48 h of infection with WNV was assessed via qPCR of target gene/actin compared with non-targeting control cells which was defined as 100% expression (n = 3). (b) WNV burdens in human macrophages after RNAi silencing. After 36 h of transfection, macrophages were infected with WNV (MOI = 1) for 48 h and viral load was quantified by qPCR. Data shown are the means ± SEM (*p < 0.05, ** p < 0.01, ***p < 0.001, T-test). Representative results from at least three independent experiments with successful RNAi silencing (>70%).
Figure 4Key signaling pathways modulated by WNV infection. Genes within selected pathways identified in the RNAseq analysis were placed on the map using annotation information from Gene Ontology, KEGG Pathway, Biocarta Pathway, PANTHER and Reactome. Transcriptional regulation in response to WNV in human macrophages is indicated by boxes (black, unchanged; red increase in gene expression; blue for decreased expression). Interactions between WNV proteins and host components are based on previous reports and are shown in grey.